Stanley Shaw, M.D., Ph.D. (MGH, Cardiology) leads a group that seeks new ways to phenotype patients and understand disease biology, through a combination of patient-focused studies, bioinformatics and chemical biology. The overall goal is to use novel phenotypes to study disease mechanisms, understand the function of disease alleles for genetically complex diseases, and devise new therapeutic approaches. He studies diabetes and metabolic disease through several approaches: 1) he directs a high-throughput chemical screening center within the MGH Center for Systems Biology; 2) he studies a large cohort of ~65,000 patients with type 2 diabetes or at risk for cardiovascular and metabolic disease within the Partners Healthcare electronic medical record, whose phenotypes are analyzed in concert with biospecimens obtained as discarded samples, which yield cells for genetic and epigenetic characterization; and 3) his group recently developed a smartphone app to understand the relations between health behaviors (diet, exercise, medications) and glucose control in type 2 diabetes. Finally, he is launching an NIH-funded project to study the stool microbiome in relation to metabolic disease (diabetes, metabolic syndrome) and cardiovascular disease in the Framingham Heart Study.